Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82461 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL2438955 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL2763479 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL186279 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL82462 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL17514076 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL14959742 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL1131702 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL8120379 | 0.89 | DPP4 (0.52) | DPP4KDM4EADRA2AADRA2CLMNA | |
| Alcohol SCHEMBL8325116 | 0.89 | KDM4E (0.57) | DPP4KDM4EADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104679-A1 | PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-22 | — | — | WO | disclosed |
| WO-2018039642-A1 | COMPOSITIONS AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-03-01 | — | — | WO | disclosed |
| US-20170145033-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| WO-2010123997-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145033-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | DPP4 168/4885KDM4E 257/4885ADRA2A 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.